Literature DB >> 22674458

Clinical severity of Huntington's disease does not always correlate with neuropathologic stage.

Jagan A Pillai1, Lawrence A Hansen, Eliezer Masliah, Jody L Goldstein, Steven D Edland, Jody Corey-Bloom.   

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a triplet-repeat, CAG expansion mutation. Although CAG repeat length is thought to correlate with pathologic burden and disease severity, considerable variability in clinical phenotype remains. This study examined whether neuropathologic burden at autopsy corresponded with severity of clinical phenotype in HD. The brains of 24 patients with a clinical and genetic diagnosis of HD were analyzed at autopsy. Subjects were stratified on the basis of Vonsattel staging as mild/moderate (stage 1-2; n = 7) or severe (stage 3-4; n = 17). Clinical severity was assessed on the basis of the Mini-Mental State Examination (MMSE; 0-30) and two Unified Huntington's Disease Rating Scale (UHDRS) functional components: the Independence Scale (10-100) and the Total Functional Capacity (0-13). Mild/moderate subjects were significantly older, had lower CAG repeat lengths, and greater fixed brain weights than those classified as severe. Patients who were pathologically classified as severe at autopsy were, on average, younger at age of onset and death and less well educated. Despite obvious clinical and pathological differences between mild-moderate and severe HD subjects at autopsy, mean MMSE scores of the two groups before death were surprisingly similar. Correlations between Vonsattel stage and functional assessment scores before death were low and not statistically significant. Our results suggest that the extent of striatal changes in HD may not always correlate with clinical disease severity as measured by UHDRS functional scales.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22674458      PMCID: PMC3412903          DOI: 10.1002/mds.25026

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

1.  A comparison of two brief screening measures of cognitive impairment in Huntington's disease.

Authors:  Laura Mickes; Mark Jacobson; Guerry Peavy; John T Wixted; Stephanie Lessig; Jody L Goldstein; Jody Corey-Bloom
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

2.  Clinical and neuropathologic assessment of severity in Huntington's disease.

Authors:  R H Myers; J P Vonsattel; T J Stevens; L A Cupples; E P Richardson; J B Martin; E D Bird
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

3.  Rate of functional decline in Huntington's disease. Huntington Study Group.

Authors:  K Marder; H Zhao; R H Myers; M Cudkowicz; E Kayson; K Kieburtz; C Orme; J Paulsen; J B Penney; E Siemers; I Shoulson
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

4.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

5.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study.

Authors:  S E Starkstein; J Brandt; F Bylsma; C Peyser; M Folstein; S E Folstein
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

6.  Genetically confirmed clinical Huntington's disease with no observable cell loss.

Authors:  M Caramins; G Halliday; E McCusker; R J Trent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

7.  Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases.

Authors:  T L Jernigan; D P Salmon; N Butters; J R Hesselink
Journal:  Biol Psychiatry       Date:  1991-01-01       Impact factor: 13.382

8.  Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study.

Authors:  K A Bamford; E D Caine; D K Kido; W M Plassche; I Shoulson
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

9.  Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.

Authors:  S M de la Monte; J P Vonsattel; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1988-09       Impact factor: 3.685

10.  Predictors of neuropathological severity in 100 patients with Huntington's disease.

Authors:  Adam Rosenblatt; Margaret H Abbott; Lisa M Gourley; Juan C Troncoso; Russell L Margolis; Jason Brandt; Christopher A Ross
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

View more
  4 in total

1.  Clinical and genetic investigation of a Brazilian family with Huntington's disease.

Authors:  L A Agostinho; M Spitz; J S Pereira; C L A Paiva
Journal:  Funct Neurol       Date:  2016 Jul-Sep

2.  Learning fast accurate movements requires intact frontostriatal circuits.

Authors:  Britne Shabbott; Roshni Ravindran; Joseph W Schumacher; Paula B Wasserman; Karen S Marder; Pietro Mazzoni
Journal:  Front Hum Neurosci       Date:  2013-11-13       Impact factor: 3.169

3.  DYNLT1 gene expression is downregulated in whole blood of patients at different Huntington's disease stages.

Authors:  S M Rosseto; T A Alarcon; D M C Rocha; F M Ribeiro; S S G Ferguson; C Martins-Silva; M R Muniz; P F Costa; D A Guimarães; Rita G W Pires
Journal:  Neurol Sci       Date:  2020-09-29       Impact factor: 3.307

4.  Examination of Huntington's disease in a Chinese family.

Authors:  Mingxia Yu; Xiaogai Li; Sanyun Wu; Ji Shen; Jiancheng Tu
Journal:  Neural Regen Res       Date:  2014-02-15       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.